Floatz logo

DEXAMETHASONE

Bispecific Antibody

PfizerSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Bispecific Antibody cohort.

Asset / SponsorPhaseRating
Benadryl
Pfizer
Phase 2B
Elranatamab
Pfizer
Phase 2B
Mezigdomide
Pfizer
Phase 2B
Polatuzumab Vedotin
Li Zhiming
Phase 2CCC
Glofitamab
Li Zhiming
Phase 2CCC

View all 11

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →